Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SP-624
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Recipient : Firefly Neuroscience
Deal Size : Inapplicable
Deal Type : Inapplicable
Firefly Neuroscience Uses Brain Analytics Platform in Phase 1 SP-624 Study
Details : SP-624 is a first-in-class SIRT6 activator, small molecule drug candidate, which is being evaluated for the treatment of patients with major depressive disorder.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 15, 2024
Lead Product(s) : SP-624
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Recipient : Firefly Neuroscience
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SP-624
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Arrivo Begins Phase 1 Study of SP-624 For Women with Major Depressive Disorder
Details : SP-624 is a novel SIRT6 activator, small molecule drug candidate, which is being evaluated for the treatment of major depressive disorder.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 10, 2024
Lead Product(s) : SP-624
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RABI-767
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Arrivo Gets FDA Fast Track for RABI-767 in Acute Pancreatitis
Details : RABI-767 is a novel, small molecule lipase inhibitor that halts the highly toxic cascade of fat necrosis, systemic toxicity, organ failure and mortality in severe acute pancreatitis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 15, 2024
Lead Product(s) : RABI-767
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SP-624
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Arrivo Bio Initiates Phase 2b Clinical Trial for Major Depressive Disorder with SIRT6
Details : SP-624 is a novel SIRT6 activator, small molecule drug candidate, which is being evaluated for the treatment of major depressive disorder.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 16, 2024
Lead Product(s) : SP-624
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SP-624
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Orlando Health Ventures
Deal Size : $45.2 million
Deal Type : Series B Financing
ArrivoBio Raises $45M in Series B Financing to Advance Pipeline
Details : Arrivo will advance its first-in-class treatment for major depressive disorder, SP-624, through Phase 2b/3 trial and complete a Phase 2 study with its novel treatment to prevent patients with pancreatitis advancing to severe acute pancreatitis, RABI-767.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 29, 2023
Lead Product(s) : SP-624
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Orlando Health Ventures
Deal Size : $45.2 million
Deal Type : Series B Financing
Lead Product(s) : SP-624
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Arrivo BioVentures Closes Enrollment in Large Phase 2 Clinical Trial for Major Depressive Disorder
Details : SP-624 has a novel epigenetic mechanism to enhance neuroplasticity in brain regions involved in depression, namely the hippocampus and prefrontal cortex.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : SP-624
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable